Moreover, it has been shown that PROTAC is a good strategy for combating on-target toxicity, such as thrombocytopenia caused by Bcl-xL inhibition, by taking advantage of the differential context expression of E3 ligase, von Hippel-Lindau (VHL) and celeblon (CRBN) 34-36. The gene discussed is CRBN; the disease is Thrombocytopenia.